"We are grateful for the continued support of our investors, whose confidence reflects both the progress of our clinical programs and the promise of our Med-Oligo™ platform. This financing positions us to accelerate the pivotal development of AHB-137, expand our global clinical footprint, strengthen our platform and pipeline, and advance our long-term vision of delivering a functional cure for people living with chronic hepatitis B and beyond."
"Proceeds from the financing will be used to advance the clinical development of AHB-137, AusperBio's lead product candidate, including the ongoing pivotal trial, multiple Phase II combination studies, and expansion into global Phase II development. The funds will also support further advancement of the company's proprietary Med-Oligo™ ASO platform, progression of its preclinical pipeline, scaling-up of commercial manufacturing partnerships, and long-term pipeline growth."
AusperBio completed a $63 million Series B2 financing co-led by Qiming Venture Partners and a global strategic investor, with participation from HanKang Capital, CDH Investments, YuanBio Venture Capital, Sherpa Capital, and Genesis Capital. The financing will advance AHB-137 through a pivotal trial, multiple Phase II combination studies, and expanded global Phase II development. Funding will also accelerate progress of the proprietary Med-Oligo™ ASO platform, support the preclinical pipeline, scale commercial manufacturing partnerships, and enable long-term pipeline growth. The company aims to position AHB-137 as a backbone therapy toward a functional cure for chronic hepatitis B.
Read at Silicon Valley Journals
Unable to calculate read time
Collection
[
|
...
]